Reuters logo
BRIEF-Paratek Pharma announces new microbiology data findings
April 24, 2017 / 11:19 AM / 7 months ago

BRIEF-Paratek Pharma announces new microbiology data findings

April 24 (Reuters) - Paratek Pharmaceuticals Inc:

* New microbiology data from Paratek Pharmaceuticals show omadacycline effective against most common skin infections and pathogens, including MRSA

* Also presented full clinical efficacy, safety and tolerability results from study, which is known as oasis

* Paratek Pharma - full results from oasis study demonstrate efficacy, safety of omadacycline versus linezolid in acute bacterial skin, skin structure infections Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below